Elanco delivers strong Q1 results as innovation drives growth 

USA – Elanco Animal Health, one of the largest independent animal health companies in the world, reported stronger-than-anticipated results for the first quarter of 2025, citing momentum in both its pet and farm animal health segments as key drivers. 

The company posted a revenue of US$1.193 billion for the quarter, down 1% year-over-year, but representing a 4% rise on an organic constant currency basis, alongside solid adjusted EBITDA and earnings per share.

The results were disclosed on May 14, with Elanco President and CEO Jeff Simmons expressing optimism for the months ahead. 

“Our diverse portfolio delivered 4% organic constant currency revenue growth, with accelerating Pet Health trends in March and April, and consistently strong execution in Farm Animal,” Simmons said. 

Product momentum drives performance

The company’s adjusted EBITDA reached US$276 million, accounting for 23.1% of total revenue, while adjusted net income stood at US$184 million, or US$0.37 per share. 

Elanco’s net leverage ratio ended the quarter at 4.4x adjusted EBITDA, with plans underway to reduce it further by year-end.

Much of the growth came from recent product launches that are gaining traction in key markets. 

For example, Credelio Quattro, a broad-spectrum parasiticide for dogs, has captured approximately 10% of U.S. veterinary clinic sales in its category. 

Meanwhile, Zenrelia, Elanco’s dermatology treatment, is now in use at about 11,000 U.S. clinics and has entered several international markets. Additional approvals are anticipated in 2025.

In the UK, Elanco launched AdTab, its oral flea and tick treatment, in April, with sales doubling year-over-year. On the livestock side, the methane-reducing feed additive Bovaer has seen usage double since February, with supporting data submitted for expanded claims.

Financial outlook raised for 2025

Elanco has increased its full-year revenue guidance to between US$4.51 billion and US$4.58 billion, up from previous estimates by US$65 million to US$ 70 million. 

Innovation revenue targets have also been revised upward, now expected to reach US$660 million to US$740 million for the year. The company reiterated its adjusted EBITDA forecast of US$830 million to US$870 million and adjusted EPS guidance of US$0.80 to US$ 0.86.

Additionally, Elanco announced a US$295 million agreement to monetise certain U.S. royalties and milestones associated with lotilaner starting in the second quarter. 

Proceeds from the deal, combined with improved working capital and favourable currency movements, are expected to help reduce gross debt by US$450 million to US$500 million this year. Elanco now targets a year-end net leverage ratio between 3.9x and 4.3x.

While Simmons acknowledged macroeconomic uncertainty, including a projected US$16–US$20 million impact from tariffs on adjusted EBITDA, he remained upbeat. 

“Our durable portfolio and solid momentum bolster our confidence in sequential acceleration of revenue growth to deliver our 2025 goals while creating long-term value for shareholders and society,” he said.

Legal troubles emerge

However, the company’s upbeat financials come amid ongoing legal challenges. Bragar Eagel & Squire, P.C., a shareholder rights law firm, recently announced that it is investigating potential claims against Elanco on behalf of long-term investors. 

The investigation follows a class action lawsuit filed on October 7, 2024, concerning alleged violations of federal securities laws during the period from November 7, 2023, to June 26, 2024.

The complaint alleges that Elanco misled investors about the safety of Zenrelia and its regulatory timeline for Zenrelia and Credelio Quattro. 

According to the filing, Elanco overstated its business prospects and made materially false and misleading statements regarding product readiness and approval timelines.

The investigation focuses on whether Elanco’s board of directors breached fiduciary duties by failing to disclose material risks, potentially leaving the company exposed to reputational and financial damage just as its innovation pipeline begins to pay off.

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World, and follow us on our WhatsApp channel for updates.